Efficacy of intravenous eptifibatide in primary percutaneous coronary intervention patients

Rozita Jalalian 1, Samad Golshani 1, Hossein Farsavian 2, Mahsa Vatani 3, Ali Asghar Farsavian 1*

Author Affiliations:
1. Department of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran
2. Department of Vascular Surgery, Mazandaran University of Medical Sciences, Sari, Iran
3. Department of Cardiology, Mazandaran University of Medical Sciences, Sari, Iran

* Corresponding Author:
Ali Asghar Farsavian,
Department of Cardiology, Faculty of Medicine, Cardiovascular Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
E-mail: dralicardio@yahoo.com

DOI
10.25122/jml-2021-0035

Dates
Received: 27 February 2021
Accepted: 18 April 2021

ABSTRACT
Early and complete restoration of blood flow in closed coronary arteries is the main goal in treating patients with myocardial infarction. Primary angioplasty is not always successful in establishing myocardial blood flow. Although the strategy of adding eptifibatide leads to better blood flow, its value as part of a routine strategy is questionable. Therefore, this study was performed to evaluate the efficacy of intravenous eptifibatide in primary percutaneous coronary intervention (PCI) patients. This clinical, randomized, double-blind trial was performed on patients aged 20-80 years undergoing primary PCI. The patients were selected for study by convenience sampling and were randomly divided into two equal groups. The first group was treated with intravenous eptifibatide immediately before angioplasty with heparin. The second group received only coronary angioplasty with heparin. After data collection, statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS) software, version 16. A total of 104 patients were enrolled in the study, and there were no statistically significant differences in terms of age (P=0.188), gender (P=0.345), risk factor (P>0.05), or history of PCI (P=0.199). Mean thrombolysis in myocardial infarction (TIMI) score was not significant between the two groups after receiving the drug and performing angioplasty (P>0.05), and the rate of ejection fraction was 46.33±6.69 in patients receiving eptifibatide and 47.54±4.67 in the heparin group, which was not statistically significant (P=0.884). We found that eptifibatide improves clinical indexes in patients undergoing primary PCI, but these differences were not significant in the two groups.

KEYWORDS: eptifibatide, heparin, primary PCI.

INTRODUCTION
Coronary artery disease is one of the most common causes of death worldwide. Nearly one-third of Americans over the age of 35 die from this disease. Coronary artery disease refers to the pathological processes of atherosclerosis that affect the coronary arteries [1, 2]. Treatment of these patients can be done through medication or invasive strategy, and decisions are made for each person according to personal circumstances [3, 4]. Initially, complete and stable coronary blood flow is an essential criterion for standard treatment of patients suffering from myocardial infarction with ST-segment elevation. Fibrinolytic treatment will reduce mortality in patients immediately after the onset of symptoms [5], but there are some limitations. Fibrinolytic treatment normalizes coronary blood flow in
only 60% of patients and has a high risk of bleeding and hemorrhagic events. The treatment of choice for patients with ST-Elevation Myocardial Infarction (STEMI) is primary percutaneous coronary intervention (PCI), in which the rate of bleeding is lower [6]. However, the movement of atherothrombotic material during primary PCI is very common in STEMI patients. This can lead to obstruction of the distal arteries and improper myocardial perfusion, which is associated with larger infarcts, impaired ventricular function, and increased mortality.

Thrombosis and vascular debris may move and form plaques in the microvascular system, causing myocardial dysfunction and necrosis [7]. There are many therapeutic strategies to improve microvascular perfusion after primary PCI, such as thrombus aspiration, GP2b/3a administration (intracoronary bolus), and others. Eptifibatide is an antiplatelet drug that reversibly inhibits the binding of fibrinogen, Von Willebrand factor, and other adhesive molecules to the platelet glycoprotein receptor IIb/IIIa; it is usually used in combination with aspirin and a p2y12 inhibitor and as an anti-coagulant treatment for acute coronary syndrome, myocardial infarction, and patients undergoing PCI. The half-life of the drug is about 2.5 hours, and about 25% of it can bind to plasma proteins. The drug metabolite is about 5% of the total body clearance, and it is excreted through urine [9]. Similar studies have investigated the long-term efficacy of eptifibatide on the ejection fraction (EF) and myocardial perfusion [5, 6, 10]. Therefore, this study was performed to evaluate the effectiveness of intravenous eptifibatide in improving EF and myocardial perfusion in primary PCI patients and to assess the rate of bleeding complications of this drug.

MATERIAL AND METHODS

This clinical, randomized, and double-blind trial was performed on patients aged 20–80 years referred to Mazandaran Heart Hospital, Iran, who underwent primary PCI with an acute STEMI clinical picture from July 2018 to April 2019. Patients were selected by convenience sampling and were randomly divided into one of two intervention groups by cardiovascular assistants. These patients did not know which group they were in; then, patients who met the inclusion criteria were included in the study.

Inclusion criteria

- Typical ischemic chest pain over 30 minutes;
- ST-segment elevation greater than one millimeter in at least two leads;
- All STEMI patients who were candidates for primary PCI;
- Myocardial infarction that did not last more than 12 hours.

Exclusion criteria

- Rescue PCI after treatment with thrombolytics;
- Need for emergency Coronary artery bypass grafting (CABG);
- Cardiogenic shock;
- Life expectancy less than 6 months;
- Patient dissatisfaction;
- Age under 18 years and over 80 years;
- Evidence of previous myocardial infarction seen on an electrocardiogram;
- Contraindications to the use of eptifibatide;
- Left Bundle Branch Block (LBBB);
- Observing TIMI grade 3 flow during primary angiography;
- Kidney failure;
- Use of GP2b/3a drugs over the last two weeks.

Sample size

The sample size of this research was calculated based on the following statistical formula:

\[ n = \frac{(z_{\alpha} + z_{\beta})^2 \sigma^2}{(\mu_1 - \mu_2)^2} = 102 \]

\[ \alpha=0.05, \ \beta=0.1, \ \sigma=15.65, \ \mu_1=38.3, \ \mu_2=43.4 \]

\[ 102^*1.2=124 \]

By considering a 20% of sample loss, mean EF before and after treatment, and reference results [10], the sample size was calculated to be 124 individuals.
Procedure

All patients received 300 mg of chewable aspirin and 600 mg of clopidogrel before the procedure. In all patients, a percutaneous femoral artery approach was used for catheterization. In both intervention groups, wiring of the culprit vessel was also performed, followed by balloon dottering. Predilation and thrombectomy were performed if necessary.

Group 1 included patients with TIMI 0-1; they received 100 units of heparin/kg and then underwent balloon dottering after wiring of the culprit vessel; if necessary, low-pressure balloon inflation was performed, then stenting was done. Patients in group 2 received 50 to 70 μg/kg of eptifibatide and 180 μg/kg of heparin by intravenous bolus were injected. Wiring of the culprit vessel and, if necessary, low-pressure balloon inflation were performed. Then, stenting was performed, and eptifibatide was continued as a 12-hour infusion. From all cardiac referrals, a 12-lead electrocardiogram (ECG) was taken at baseline and 90 minutes after PCI in the coronary care unit (CCU). Both electrocardiograms were examined by a blinded observer. In all patients, echocardiography was performed by one person at the beginning of admission and 3–4 days after PCI. 2D and Doppler echo parameters were measured using the standard methods. All volumes were normalized based on the body surface index. Regional wall motion was performed using a 17-segment model approved by the American Society of Echocardiography and the European Association of Echocardiography. For 2D-strain analysis, a 17-segment model of the left ventricle (LV) was prepared from apical 2, 3, and 4 chambers views and parasternal short-axis (PSAX) view at the basal, middle, and apical levels by automatic software. Positive or negative strain value was defined during systole. The global longitudinal strain (GLS), global circumferential strain (GCS), global radial strain (GRS) values were obtained by calculating the mean peak systolic strain value in the 18-segment model. In the studied patients, Ck-Mb and troponin were measured time at admission and 24 hours later.

Statistical analysis

Data were described based on the mean and standard deviation for quantitative variables, while numbers and percentages were considered for qualitative variables. The relative frequency of complications between the two groups was assessed by the Chi-Square test. Statistical analysis was performed after entering the data into the Statistical Package for the Social Sciences (SPSS) software, version 16. A significance level of 0.05 was considered.

RESULTS

A total of 104 patients were included in the study, of whom 59 were in the heparin group and 45 in the eptifibatide group. The mean age was 56.53±8.1 in the heparin group and 55.53±10.1 in the eptifibatide group. There was no statistically significant relationship between the two groups in terms of age (P=0.188). The eptifibatide group consisted of 34 (75.6%) males and 11 (24.4%) females. The heparin group included 49 (83.1%) males and 10 (16.9%) females. There was no statistically significant difference between the two groups in terms of gender (P=0.345).

In the eptifibatide group, history of diabetes, hypertension, and chronic kidney disease were revealed for 18 patients (40%), 16 patients (35.6%) and 1 patient (2.2%) respectively, while 37 (60%), 29 (64.4) and 44 patients (97.8%) had no history of these diseases, respectively. In the heparin group, history of diabetes, hypertension, and chronic kidney disease were recorded for 23 patients (39.4%), 18 (30.5%) and 1 patient (1.7%), respectively, whereas 36 patients (60.6%), 41 patients (69.5 %) and 58 patients (98.3%) had no history of these diseases, respectively which did not show a statistically significant difference (P=0.916, P=0.587, P=0.846, respectively) (Figure 1).

Regarding the history of PCI in the eptifibatide group, 3 patients (6.7%) had a history of PCI, and 42 patients (93.3%) had no history. In the heparin group, 1 patient (1.7%) had a history of PCI and 38 patients (98.3%) had no PCI history. Overall, there was no statistically significant difference between the two groups (P=0.191) (Figure 2).

Participants were evaluated for chest pain before and after PCI. In the eptifibatide and heparin groups, 28 patients (62.3%) and 53 patients (89.9%) had chest pain before PCI, respectively, and 17 patients (37.7%) and 6 patients (10.1%) had no chest pain before PCI. After PCI, 45 patients (100%) and 58 patients (98.1%) did not have chest pain, and only one person in the heparin group had chest pain after PCI; these findings did not show a statistically significant difference in terms of chest pain before and after PCI (P=0.510, P=0.734). Participants were evaluated for wall motion index before and after PCI.
the intervention in two treatment groups. The study results showed that the mean wall motion index before the intervention was 1.18±0.19 in the heparin group and 1.22±0.21 in the eptifibatide group. After the intervention, the wall motion index was 1.5±0.23 in the heparin group and 1.22±0.21 in the eptifibatide group. There was no statistically significant difference between the results before and after the wall motion index (P=0.061, P=0.08).

Our findings showed that patients in the eptifibatide group had lower CK-MB values (average of 156.49±143.447) than the heparin group who had an average of 121.88±103.155, but the two groups did not show a statistically significant difference in CK-MB levels before and after the intervention (Table 1 and Figure 3; P>0.05).

Left ventricular ejection fraction (LVEF) before intervention in patients in the heparin group was 40.59±5.5. In the eptifibatide group, it was 39.56±8.5%. After the intervention, LVEF was 47.3±4.6 in the heparin group and 46.3±6.6 in the eptifibatide group. No significant difference was found between the two groups regarding LVEF before and after the intervention (P=0.948, P=0.884; Figure 4).

The results showed that sum ST resolution above 70% was seen in 74.5% cases in the heparin group and 73.3% cases in the eptifibatide group. Furthermore, a sum ST Resolution of 50% was found to be 88.1% and 91.1% in the heparin and eptifibatide groups, respectively, which was not statistically significant between the two groups (P=0.341; Table 2).

Participants were examined for mitral regurgitation before and after the intervention in two groups (Table 3). The results revealed no statistically significant difference between the two groups in terms of MR before and after the intervention (P>0.05).

The results of Table 4 showed that there was no significant difference between the two groups in terms of TIMI flow before and after the intervention based on the territory.

**DISCUSSION**

Early and complete restoration of blood flow in closed coronary arteries is the main goal in treating patients with myocardial infarction. Primary angioplasty is not always successful in restoring myocardial blood flow, despite success in the opening of the epicardial coronary arteries. Eptifibatide is a glycoprotein IIb/IIIa receptor antagonist. Although the strategy of adding eptifibatide leads to better blood flow, its value as part of the routine strategy is questionable, according to the results of previous studies [11, 12]. Therefore, this study aimed to evaluate the effectiveness of intravenous eptifibatide in improving myocardial perfusion and the rate of hemorrhagic complications in primary PCI patients.

The results of the present study demonstrated that eptifibatide has no significant advantage in the coronary artery flow compared to the usual treatment of patients. In the present study, no significant difference was found in terms of TIMI flow between the eptifibatide and heparin treatment groups. However, Gibson et al. reported that early administration of eptifibatide was associated with improved...
epicardial flow and increased myocardial perfusion in patients with acute myocardial infarction, which was not consistent with the results of the present study [5].

Contrary to the results of the present study, other studies have suggested that the administration of eptifibatide is associated with improved myocardial perfusion [5, 13]. In other words, this drug is effective in correcting perfusion parameters and the results of laboratory studies, which show an increase in clot dissolution when increasing eptifibatide concentration. In 2011, Mahmoudi et al. reported that the eptifibatide group showed a 6-month benefit in terms of mortality compared to the adjuvant group at Washington Hospital [14].

In the current study, the percentage of ST-segment resolution after treatment in the eptifibatide group was higher than in the heparin group. This means that the effect was higher in the eptifibatide group, but no statistically significant difference was found between the two groups in this regard. In fact, most of the variables in the intervention group were better, but their differences were not significant compared to the control group.

Zeymer et al. compared the effects of early and delayed injection of eptifibatide in patients with STEMI; out of a total of 102 patients, 2 in each group had bleeding complications, but no difference has been found between the two groups, which were consistent with the results of our study. Also, no statistical difference was found between the two groups in terms of ST-segment resolution rate, and TIMI flow rate was similar in both groups after angioplasty, results which are somewhat consistent with our findings [15].

The Joint Canada/United States Survey of Health (JCUSH) divided patients undergoing elective or emergency PCI into two groups, one receiving placebo and the other receiving eptifibatide along with aspirin and heparin. Eptifibatide infusion was continued for 24–28 hours after angioplasty or until the patient was discharged from the hospital. The results of the aforementioned study showed that the rate of major and minor bleeding was higher in the eptifibatide group, which was not consistent with the results of our study [16]. In the study of Le May et al., it was found that the rate and frequency of bleeding complications were significantly higher in the eptifibatide group than in the control group. The reasons for the low rate of bleeding in the present study include the accuracy and skill of the operator, the careful selection of patients based on stringent inclusion and exclusion criteria, and the infusion of eptifibatide with a shorter duration (12 hours) [17].

In another study by Soon et al., two groups of patients (who received intracoronary bolus and intravenous injection) were evaluated for myocardial infarction. Patients in the intervention group received an eptifibatide intracoronary bolus dose, and patients in the control group received an eptifibatide infusion for 18 hours after PCI. The results of the study revealed that both groups were in a favorable prognosis in terms of angiographic findings [18]. In addition, Gibson et al. compared the effect of intracoronary versus intravenous
epitifibatide during PCI. The results of their study showed that epicardial TIMI flow had a significant increase in patients receiving intravenous epitifibatide compared to the intracoronary route [5], indicating that epitifibatide increases myocardial perfusion.

CONCLUSION

Eptifibatide improves clinical indexes in patients undergoing primary PCI, but these rates were not found to be statistically significant. Thus, further studies are needed to confirm or refute these data.

ACKNOWLEDGMENTS

Ethical approval
The approval for this study was obtained from the Ethics Committee of Mazandaran University of Medical Sciences (approval ID: ir.mazums.rec.1397.1280).

Consent to participate
Written informed consent was obtained from the participants.

Conflict of interest
The authors declare that there is no conflict of interest.
With Thrombus Aspiration

Clinical Perspective: The Undergoing Primary Percutaneous Coronary Intervention With ST-Segment Elevation Myocardial Infarction

Intravenous Administration of Abciximab in Patients

Nijsten MW, Hillege HL

2013;165(3):437–43.

study. International journal of cardiology.

primary percutaneous coronary intervention: the ICT-AMI patients with ST-elevation myocardial infarction undergoing administration following upstream intravenous treatment in department before primary percutaneous coronary intervention.

et al.

2013;14(1):42–4.

10. Pakbas B, Moshaverinia N, Ali-Saeidi A, Taheri-Nejad M, Shahmirzae R. Evaluation of the effect of integrilin in primary coronary angioplasty on mortality and echocardiographic findings in patients with acute myocardial infarction. Anak Medical University Journal (AMUJ). 2014;17(6):11–20.

11. Ramani G, Yu W, Ip S, Sali P, Chang LW, Ioannou GC, et al. Intracoronary Diagnostic Procedures and Imaging Techniques Versus Angiography Alone in Coronary Artery Stenting: Comparative Effectiveness Review. 2015.

12. Zozani, M. A., et al. "Safety and effectiveness of everolimus compared with sirolimus and tacrolimus in preventing kidney transplantation rejections: a systematic review and meta-analysis". Tehran University Medical Journal. 2015;17(6):43–47.

13. Gibson CM, de Lemos JA, Murphy SA, Marble SJ, McCabe CH, Cannon CP, et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001;103(21):2550–4.

14. Mahmoudi M, Delhaye C, Wakabayashi K, Torp-Pedersen R, Xue Z, Sudesh WO, et al. Intracoronary Versus Intravenous Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Journal of interventional cardiology. 2011;24(4):551–6.

15. Zeymer U, Zahn R, Schürle R, Janse W, Gehrle E, Gitt A, et al. Early epifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: results of the randomized Integrilin in acute myocardial infarction (INTAMI) pilot trial. European heart journal. 2006;26(9):971–7.

16. Investigators, E., Novel dosing regimen of epifibatide in planned coronary stent implantation (EPFRIT): a randomized, placebo-controlled trial. Lancet. 2000;356(9247):2037–44.

17. Le May MR, Wells GA, Glover CA, Sei-DW, Fivett M, Marquis JF, et al. Primary Percutaneous Coronary Angioplasty With and Without Epifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Intracoronary-Evacetrapib Versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST). Circulation: Cardiovascular Interventions. 2009;2(4):330–8.

18. Soon D, Ho HH, Loh KK, Ooi YW, Foo D, Jalayy FH, et al. Clinical outcomes of intracoronary epifibatide bolus only versus intracoronary bolus and intravenous infusion of epifibatide in primary percutaneous coronary intervention. Acute cardic care. 2012;14(1):42–4.

REFERENCES

1. Hanson MA, Envedt MT, Angino SL, Apurvauma AO, Hanson TR. Coronary artery disease. Primary Care Clinics in Office Practice. 2013 Mar 1; 40(1):1–6.

2. Hanson GK. Inflammation, atherosclerosis, and coronary artery disease. New England Journal of Medicine. 2000; Apr 21; 352(9):865–95.

3. Baeck AA, Gogol Y, Handberg EM, Coepper-DeHoff RM, Pippin CJ. Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. The American journal of medicine. 2013 Feb 28; 128(2):137–43.

4. Bliden KP, Singla A, Gasheff MG, Toli P, Tabrizchi A, Koo G, Goyer K, Singh M, Francois CJ, Stapleton D, Tantry US. Statin therapy and thrombocytopenia in patients with coronary artery disease treated with high-dose aspirin. Thrombosis and haemostasis. 2014;112(2):323–31.

5. Gibson CM, Kirtane AJ, Murphy SA, Rohrbeck S, Menon V, Linx J, et al. Early initiation of epifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial. American heart journal. 2006;152(4):668–75.

6. Hansson MA, Fareed MT, Argenio SL, Agunwamba AO, Hanson TR. Coronary artery disease. Primary Care: Clinics in Office Practice. 2013 Mar 1; 40(1):1–6.

7. Gibson CM. Intracoronary eptifibatide bolus administration following upstream intravenous treatment in patients with STElevation myocardial infarction underlying primary percutaneous coronary intervention: the ICT-AMI study. International journal of cardiology. 2013;165(3):437–43.

8. Deible AJ, Jennison LK, Te-heng J, Novec G, Echhart AD, Gibson CM. Intracoronary epifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein Ilb/Ilia receptor occupancy and platelet function: the Intracoronary Epifibatide (ICE) Trial. Circulation. 2010;121(8):784–91.

9. Ibrahim Shah, Shakeel O Khan, Rohitender Malhotra, Tim Fischell. Epifibatide: The evidence for its role in the management of acute coronary syndromes. Dovepress. 2009;4:49–63.

10. Puthuc PJ, Moshaverinia N, Ali-Saeidi A, Taheri-Nejad M, Shaikhionvarz R. Evaluation of the effect of integrilinimprimy coronary angioplastymortality and echocardiographicfindingspatients with acute myocardial infarction. Anak Medical University Journal (AMUJ). 2014;17(6):11–20.

11. Zeymer U, Zahn R, Schürle R, Janse W, Gehrle E, Gitt A, et al. Early epifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: results of the randomized Integrilin in acute myocardial infarction (INTAMI) pilot trial. European heart journal. 2006;26(9):971–7.

12. Zozani, M. A., et al. Primary Percutaneous Coronary Angioplasty With and Without Epifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Intracoronary-Evacetrapib Versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST). Circulation: Cardiovascular Interventions. 2009;2(4):330–8.

13. Soon D, Ho HH, Loh KK, Ooi YW, Foo D, Jalayy FH, et al. Clinical outcomes of intracoronary epifibatide bolus only versus intracoronary bolus and intravenous infusion of epifibatide in primary percutaneous coronary intervention. Acute cardic care. 2012;14(1):42–4.

14. Mahmoudi M, Delhaye C, Wakabayashi K, Torp-Pedersen R, Xue Z, Sudesh WO, et al. Intracoronary Versus Intravenous Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Journal of interventional cardiology. 2011;24(4):551–6.

15. Zeymer U, Zahn R, Schürle R, Janse W, Gehrle E, Gitt A, et al. Early epifibatide improves TIMI 3 patency before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: results of the randomized Integrilin in acute myocardial infarction (INTAMI) pilot trial. European heart journal. 2006;26(9):971–7.

16. Investigators, E., Novel dosing regimen of epifibatide in planned coronary stent implantation (EPFRIT): a randomized, placebo-controlled trial. Lancet. 2000;356(9247):2037–44.

17. Le May MR, Wells GA, Glover CA, Sei-DW, Fivett M, Marquis JF, et al. Primary Percutaneous Coronary Angioplasty With and Without Epifibatide in ST-Segment Elevation Myocardial Infarction: A Safety and Efficacy Study of Intracoronary-Evacetrapib Versus Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction (ASSIST). Circulation: Cardiovascular Interventions. 2009;2(4):330–8.

18. Soon D, Ho HH, Loh KK, Ooi YW, Foo D, Jalayy FH, et al. Clinical outcomes of intracoronary epifibatide bolus only versus intracoronary bolus and intravenous infusion of epifibatide in primary percutaneous coronary intervention. Acute cardic care. 2012;14(1):42–4.